Izraeli Shai, Shochat Chen, Tal Noa, Geron Ifat
Childhood Leukemia Research Section, Department of Pediatric Hemato-Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Department of Molecular Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel.
Childhood Leukemia Research Section, Department of Pediatric Hemato-Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel; Department of Molecular Human Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel; Migal Galilee Technology Center, Kiryat Shmona, Israel; Tel Hai College, Upper Galilee 12210, Israel.
Cancer Lett. 2014 Sep 28;352(1):15-20. doi: 10.1016/j.canlet.2014.02.009. Epub 2014 Feb 22.
The successful therapy of childhood leukemia has been characterized by careful personalized adaptation of therapy by risk stratification. Yet almost all drugs are relatively non-specific. To achieve greater precision in therapy, druggable targets and specific targeting drugs are necessary. Here we review the recent discoveries of cytokine receptors and their signaling components in high risk leukemias and the potential approaches to target them.
儿童白血病的成功治疗一直以通过风险分层对治疗进行仔细的个性化调整为特征。然而，几乎所有药物都相对缺乏特异性。为了在治疗中实现更高的精准度，可成药靶点和特异性靶向药物是必要的。在此，我们综述了高危白血病中细胞因子受体及其信号传导成分的最新发现以及靶向它们的潜在方法。
